Latecomer Merck Enters Coronavirus Vaccine Field With Themis Acquisition
Company Was First To Develop An Ebola Vaccine
While Moderna and others frontrunners aim for a 2020 emergency use approval, Merck believes a more deliberate approach will pay off in the long term.
You may also be interested in...
Valneva Advances New Vaccines Agenda With Top-Line Phase III Chikungunya Data
France’s Valneva has announced positive top-line Phase III data for its investigational chikungunya vaccine, and the NASDAQ- and Euronext-listed company looks set to launch the product next year.
Merck & Co. Pivots To COVID-19 Treatments After Vaccines Disappoint
The company cited lackluster efficacy in its decision to discontinue development of V590 and V591. It will instead develop two drugs to treat COVID-19.
Merck & Co. Buys Out OncoImmune For Phase III COVID-19 Therapy
Deal snapshot: For $425m up front, the pharma obtains a Phase III recombination fusion protein that shows ability to improve hospitalized patients’ clinical status and reduce risk of death.